Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?

    Access Status
    Fulltext not available
    Authors
    Giele, C.
    Moore, H.
    Bayley, K.
    Harrison, C.
    Murphy, D
    Rooney, K.
    Keil, A.
    Lehmann, Deborah
    Date
    2007
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Giele, Carolien and Moore, Hannah and Bayley, Kathy and Harrison, Catherine and Murphy, Denise and Rooney, Kylie and Keil, Anthony D. and Lehmann, Deborah. 2007. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?. Vaccine 25: 2379-2384.
    Source Title
    Vaccine
    DOI
    10.1016/j.vaccine.2006.09.004
    Faculty
    Centre for Developmental Health
    School
    Centre for Developmental Health (Curtin Research Centre)
    Remarks

    Giele, Carolien and Moore, Hannah and Bayley, Kathy and Harrison, Catherine and Murphy, Denise and Rooney, Kylie and Keil, Anthony D. and Lehmann, Deborah (2007) Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?, Vaccine 25:2379-2384.

    Copyright 2007 Elsevier. All rights reserved

    URI
    http://hdl.handle.net/20.500.11937/20220
    Collection
    • Curtin Research Publications
    Abstract

    Enhanced surveillance for invasive pneumococcal disease (IPD) has been ongoing in Western Australia since 1996. We describe the epidemiology of invasive pneumococcal disease in children aged <2 years between 1996 and 2005. Pneumococcal conjugate vaccine has been offered to Aboriginal children and other high-risk children since July 2001 and to all Australian children since January 2005. A total of 1655 IPD cases were reported of whom 361 (55 Aboriginal) were aged <2 years. From 1996 2001 to 2002 2005, IPD incidence declined from 192 to 124/100,000/annum in Aboriginal children and from 70 to 56/100,000/annum in non-Aboriginal children. Incidence of IPD due to vaccine serotypes (VT) declined from 118 to 43/100,000/annum (p = 0.05) in Aboriginal children and from 59 to 45/100,000/annum in non-Aboriginal children (p < 0.001), with no increased incidence of disease due to non-vaccine serotypes. Continued surveillance is essential to measure the impact of the childhood pneumococcal conjugate vaccination program on IPD incidence and to identify the emergence of disease due to non-vaccine serotypes.

    Related items

    Showing items related by title, author, creator and subject.

    • Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia
      Gidding, H.; McCallum, L.; Fathima, P.; Moore, H.; Snelling, Thomas; Blyth, C.; Jayasinghe, S.; Giele, C.; de Klerk, N.; Andrews, R.; McIntyre, P. (2018)
      Background: Most studies use indirect cohort or case-control methods to estimate vaccine effectiveness (VE) of 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease (IPD). ...
    • No evidence for impaired humoral immunity to pneumococcal proteins in Australian Aboriginal children with otitis media
      Thornton, R.; Kirkham, L.; Corscadden, K.; Coates, H.; Vijayasekaran, S.; Hillwood, J.; Toster, S.; Edminston, P.; Zhang, Guicheng; Keil, A.; Richmond, P. (2017)
      Background: The Australian Aboriginal population experiences disproportionately high rates of otitis media (OM). Streptococcus pneumoniae is one of the main pathogens responsible for OM and currently no vaccine offering ...
    • Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
      Van Den Biggelaar, A.; Richmond, P.; Fuery, A.; Anderson, D.; Opa, C.; Saleu, G.; Lai, M.; Francis, J.; Alpers, Michael Philip; Pomat, W.; Lehmann, D. (2017)
      Trial design: In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.